Company announcement 01/2022

Roskilde, 10.06.2022

Apillet ApS Announces the in-vitro testing of APIVault tablet Prototype.

Apillet ApS, a Danish biotech company, develops gastro resistant enteric encapsulations for oral delivery of Biopharmaceuticals, Sensitive pharmaceuticals, Probiotics and Nutraceuticals, today announces the first prototype of the APIVault enteric technology for targeted delivery in the small intestine and the colon.

The APIVault encapsulation material is produced solely from natural materials with a combination of bacterial cellulose and cellulases as basis. The prototype is a tablet protecting the enclosed substance against enzymatic degradation and low pH in the stomach. The tablets can be programmed to release the substance at a predetermined location in the small intestine or in the colon.

Apillet has through recent development work obtained further knowledge of the protection properties, release properties and design parameters of APIVault. A formula for targeted release at locations in the small intestine and the colon has been designed. Furthermore, prototypes have been produced.

We are now testing the release properties of a model substance to further validate the APIVault. We are looking for first candidate Biopharmaceuticals, Sensitive pharmaceuticals, Probiotics or Nutraceuticals to test release properties in-vitro and in-vivo.

About APILLET ApS

Apillet ApS, (CVR-no. 41388285) is a biotech company based in Roskilde Denmark, that develops gastro resistant enteric encapsulations for oral delivery of Biopharmaceuticals, Sensitive pharmaceuticals, Probiotics and Nutraceuticals.

Further information:

CEO Anders B. Christensen, cell +45 5178 0684, email: anders.christensenapillet.com

CFO Carsten L. Petersen, cell +45 2346 2718, email: carsten.petersenapillet.com